Drugs / Lactic Acid
Lactic Acid
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER | — | 2006-10-25 | fda.gov ↗ |
Trials 44
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT06022263 | Jul 2023 → Sep 2024 | lumbar disk disease | Stayble Therapeutics | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT00679562 | Mar → Apr 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 335 trials | ||||||
| Phase 3 | NCT01158365 | Jul → Dec 2010 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00933712 | Jun → Jul 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00932945 | Jun → Jul 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00933075 | Jun → Jul 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00933569 | Jun → Jul 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00933413 | Jun → Jul 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00933257 | Jun → Jul 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00784069 | Oct → Nov 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00784121 | Oct → Nov 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00783861 | Oct → Nov 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00783640 | Oct → Nov 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00783939 | Sep 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00785590 | Aug → Sep 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00784056 | Aug → Sep 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00783666 | Aug → Sep 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00785148 | Aug → Sep 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00785720 | Aug → Sep 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00784160 | Jul → Sep 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00785655 | Jul → Sep 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00785681 | Jul → Sep 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00761800 | May 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00705744 | Apr → May 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00705276 | Apr → May 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00664391 | Jan → Feb 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00668486 | Jan → Feb 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00668668 | Dec 2007 → Jan 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00663325 | Dec 2007 → Jan 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00669058 | Dec 2007 → Jan 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00663273 | Dec 2007 → Jan 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00663390 | Dec 2007 → Jan 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00668226 | Dec 2007 → Jan 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00668577 | Dec 2007 → Feb 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00668629 | Nov 2007 → Jan 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00668889 | Nov 2007 → Jan 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00668460 | Nov 2007 → Jan 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT07401342 | Nov → Dec 2023 | — | Instituto de Oftalmología Fundación Conde de Valenciana | Completed | No outcome recorded |
| Phase 4 | NCT00881270 | Mar 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00881374 | Feb → Mar 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00881348 | Feb → Mar 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00712868 | Jun → Aug 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06327581 | Dec 2023 → Dec 2026 expected | alopecia areata | Zagazig University | Recruiting | No outcome recorded |
| — | NCT06978049 | Jan → Dec 2023 | — | Saint Andrew Hospital Constanta | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT04429308 Comparator | Aug 2026 → Dec 2027 expected | actinic keratosis | Northwestern University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07329907 Comparator | Dec 2023 → Jun 2024 | common wart, human papilloma virus infection | Benha University | Completed | No outcome recorded |
| Phase 4 | NCT00771121 Comparator | — | atopic eczema | ACO Hud Nordic AB | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-12-11 | Stayble Therapeutics | Results Stayble Therapeutics reports additional data strengthening the STA363 treatment for pain caused by disc herniation staybletherapeutics.com ↗
The phase 1b trial has shown a statistically significant effect in terms of volume changes. |
| 2024-06-25 | Stayble Therapeutics | Results Stayble Therapeutics presents positive interim data from the ongoing phase Ib study with STA363 staybletherapeutics.com ↗
The company also presents positive interim data with established safety and tolerability (primary study objective) when evaluating available blinded data from the three-month follow-up. |
| 2024-04-03 | Stayble Therapeutics | Results Abstract on STA363’s clinical effect on disc volume has been accepted for presentation at an important congress staybletherapeutics.com ↗
The result demonstrates a statistically significant reduction in both disc height and water content, which is indirectly a measure of reduced disc volume. |
| 2023-12-12 | Stayble Therapeutics | Results Stayble Therapeutics Phase IIb data support effectiveness in treating herniated discs staybletherapeutics.com ↗
In patients who received the higher dose of STA363, a statistically significant difference was observed in disc intensity and disc height, which are clear signs of reduced disc volume. |
| 2021-12-01 | Stayble Therapeutics | Results Stayble Therapeutics presented at Swedish Shareholders´ Association´s event Stora Aktiedagen Stockholm 2021 staybletherapeutics.com ↗
CEO Andreas Gerward presented the Company, the development of the injection treatment STA363 for chronic disc-related low back pain, and positive interim results from the ongoing clinical phase 2b study. |
All press releases naming this drug 13 releases
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 47 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactic Acid | “salicylic acid for individuals predisposed to oily skin and acne, mandelic acid for those with irregular pigmentation and hyperpigmentation, lactic acid for individuals with...” NCT07401342 ↗46“Chemical peels consists of a combination of Jessner's Solution: Composed of Salicylic Acid (14%), Medical Grade Lactic Acid (14%), Medical Grade Resorcinol (14%), Denatured...” NCT04429308 ↗ |
| Known as | Dermacid | “Lactic acid (Dermacid)” NCT00663390 ↗12“Lactic acid (Dermacid)” NCT00669058 ↗ “Lactic acid (Dermacid)” NCT00668577 ↗ “Lactic acid (Dermacid)” NCT00668889 ↗ “Lactic acid (Dermacid)” NCT00668460 ↗ “Lactic acid (Dermacid)” NCT00664391 ↗ “Lactic acid (Dermacid)” NCT00668486 ↗ “Lactic acid (Dermacid)” NCT00668629 ↗ “Lactic acid (Dermacid)” NCT00663325 ↗ “Lactic acid (Dermacid)” NCT00668226 ↗ “Lactic acid (Dermacid)” NCT00668668 ↗ |
| Known as | Dermacyd Breeze | “Dermacyd Breeze (Lactic Acid) Pocket BR” NCT00784121 ↗1“Lactic Acid (Dermacyd Breeze)” NCT00784069 ↗ |
| Known as | Dermacyd Femina | “Drug: Lactic Acid (Dermacyd Femina)” NCT00783640 ↗ |
| Known as | Dermacyd Femina Delicata | “Lactic acid (Dermacyd Femina Delicata)” NCT00705276 ↗ |
| Known as | Dermacyd Infantile | “Dermacyd Infantile (LACTIC ACID)” NCT00881270 ↗ |
| Known as | Dermacyd PH\_DETINBACK Tangerine Mix | “Lactic Acid (Dermacyd PH\_DETINBACK Tangerine Mix)” NCT00783939 ↗1“Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)” NCT00784160 ↗ |
| Known as | Dermacyd PH_DETINBACK | “Dermacyd PH_DETINBACK (Lactic Acid)” NCT00785720 ↗1“Dermacyd PH_DETINBACK (Lactic Acid)” NCT00785681 ↗ |
| Known as | Dermacyd PH_DETINLYN | “Dermacyd PH_DETINLYN (Lactic Acid)” NCT00785590 ↗1“Dermacyd PH_DETINLYN (Lactic Acid)” NCT00785655 ↗ |
| Known as | Dermacyd Silver Floral | “Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.” NCT00933712 ↗1“Aplication of Dermacyd Silver Floral (Lactic Acid) during 21 consecutive days” NCT00933569 ↗ |
| Known as | Dermacyd Silver Frutal | “Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).” NCT00933075 ↗ |
| Known as | Dermacyd Silver Frutal (Lactic Acid) | “Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).” NCT00933075 ↗ |
| Known as | LACTIC ACID(ND) | “Drug: LACTIC ACID(ND)” NCT00933075 ↗ |
| Known as | STA363 | “2/3 of the patients will be randomized to STA363 (lactic acid, 120 mg/mL with Omnipaque, 1.5 mL).” NCT06022263 ↗ |
| Action | Activate | “Lactic acid stimulates spontaneous secretion of vascular endothelial growth factor (VEGF)” NCT06327581 ↗ |
| Modality | Other / unclassified | “Lactic acid is a member of alpha-hydroxy acids.” NCT06327581 ↗ |
| Route | Topical | “Liquid soup to be applied in the external genital area” NCT00663273 ↗ |